Medical Science Journal for Advance Research

Copyright © The Author(s)
Vol. 7, No. 3, September 2026
e-ISSN: 2774-4892

CRISPR–Cas9 Genome Editing in Female Infertility: Molecular Targets, Therapeutic Applications and Future Perspectives

Marwa Abbas Kubba

PhD in Biotechnology, College of Science, Baghdad University, Iraq.

Corresponding Author Email: Marwa.a@sc.uobaghdad.edu.iq

ABSTRACT

Female infertility is a heterogenous clinical condition rooted in the interplay of genetic, endocrine, anatomical, and environmental factors. Variants responsible for failure of ovarian development, folliculogenesis, meiotic progression and early embryogenesis can lead to reproductive failure, whereas the highly complex genetic architectures of polycystic ovary syndrome and endometriosis have been suggested through this. CRISPR–Cas9 provides a flexible platform to investigate the mechanisms underlying these mechanisms via targeted gene disruption, sequence modification and control of expression. It is also advised that a molecular alteration ca be does not imply it is possible to regain fertility. This narrative review, reviews the controlling genetic factors of female infertility, the operating principles of older and newer CRISPR systems, and experimental uses in reproductive biology. Confirmed cases confirm gene-function analyses in human preimplantation embryos and epigenetic reloading of FMR1 in fragile X syndrome derived neurons, but these findings do not indicate ovarian rescue or better pregnancy results. Progression to the clinic is limited by tissue-specific delivery, inefficient or unpredictable DNA repair, mosaicism, off-target activity, and deleterious on-target chromosomal abberations. Base and prime editing may reduce the requirement for double-strand breaks, but introduce their own efficacy, specificity and delivery challenges. Heritable alterations also bring new ethical questions about consent, intergenerational risk, equitable access, and regulation. The immediate role of CRISPR in reproductive medicine will therefore be for disease modelling and functional validation, as opposed to mainstream medicine. Any future therapeutic intervention must demonstrate solid reproductive efficacy, be all-inclusive of the genome, and an ethically sound level of regulation.

Keywords: **Female infertility; CRISPR–Cas9; Genome Editing; Premature Ovarian Insufficiency; Reproductive Genetics; Assisted Reproductive Technology.**

Article Information

Received: July 30, 2026; Revised: August 28, 2026; Online: September 2026y

1. INTRODUCTION

The WHO defines Infertility as defined as the failure of achieving pregnancy even after 12 months of regular, unprotected sexual intercourse. It could be a result of male factors, female factors, combined factors or be of unknown origin after evaluation [1]. An estimated 17.5% of people throughout their lifetime have experienced they have been infertile, an estimated one in six individuals according to the World Health Organization [2]. This should be interpreted as total infertility, not just female infertility in the population at large. Differentiating female infertility from recurrent pregnancy loss, although the etiology of the two conditions may overlap including genetic contributors associated with the need for a reproductive genetic assessment.

Female reproductive function depends on healthy gonadal development, has a healthy and sufficient follicular reserve, is maintained via endocrine responsiveness, normal oocyte maturation, fertilization and implantation. Many contributory factors could compromise fertility at some point. Genetic changes are as diverse as chromosomal aneuploidies to highly penetrant single-gene variants and distributed susceptibility that affects multiple loci [3]. The heterogeneity in clinical presentation due to genetic and other causes, and inferring a definitive causal relationship (as opposed to, a

https://doi.org/10.46966/msjar.v7i3.473
This work is licensed under a Creative Commons Attribution 4.0 International License

biologically plausible phenomenon: e.g., lack of one allele following extensive follicular depletion do not necessarily lower ovarian reserve [3, 4]. Certain physiological barriers in disorders that are not due to the underlying genetic illness can be treated using customised treatments such as ovulation induction and in vitro fertilisation (IVF). It is not a treatment but should help to re-initiate ovulation or to allow for pregnancy, depending on the disorder for which they are employed. These studies provide a completely new paradigm for approach to conceptualisation, where there are algorithms incorporated to comb through or change molecular determinants directly. Cluster regularly interspaced short palindromic repeats, originally known as clustered regularly interspaced short palindromic repeats (CRISPR) [4,5], originated in microbial adaptive immunity and has now become an elegant, highly adaptable tool that can be used for genome engineering.

It is a narrative review of the genetics, preclinical use of CRISPR, technical limitations and implementation challenges involved with female infertility. The difference between clinical current standard approach to current routine practice and the 2nd set of treatments in the realm of research apis is made clear and is no longer a systematic review with meta-analysis. These technologies, which are what we are presently applying for the purpose of reproduction, are still predominantly experimental. The present evidence failed to support claims of an approved use of CRISPR for treating female infertility [7].

2. Genetic Determinants of Female Infertility

2.1. Ovarian development and follicular signalling

Premature ovarian insufficiency (POI) is the decrease of ovarian function before 40 years of age and can reflect an accelerated loss or dysfunction of follicles. Genetic causes include chromosomal abnormalities and variants that affect gonadal development, DNA repair, meiosis and folliculogenesis. The updated POI guideline supports genetic assessment in a diagnostic and counselling framework that acknowledges Many cases of the condition remain unexplained [3, 4]. It is imperative to understand that POI is not monogenic, but comes from a developmental defect, receptor dysfunction and loss of primordial follicles, and each circumstance presents an independent biological challenge to therapy.

The FOXL2 transcription factor is implicated in ovarian differentiation and granulosa-cell identity. Pathogenic variants have also been reported to cause blepharophimosis– ptosis–epicanthus inversus syndrome, as part of the reproductive phenotype associated with ovarian dysfunction. As there can be great variability between the genotype of a affected individual and her or his final ovarian outcome, a variant at FOXL2 should not be taken at face value in isolation of the clinical context and mode of inheritance. Loss-of-function variants in the follicle-stimulating hormone receptor gene, FSHR, can impair ovarian responses to follicle-stimulating hormone. Severe loss of receptor action can stop follicle progression and lead to hypergonadotropic hypogonadism or primary amenorrhoea [3]. Functional assays are mechanistically definable for these disorders, yet their detection alone does not guarantee that editing an cultivated ovary will re-establish fertility. Growth differentiation factor 9 (GDF9) and bone morphogenetic protein 15 (BMP15) are two oocyte-derived factors that transduce signals from oocytes to surrounding granulosa cells. Their signalling pathways are the key for granulosa-cell differentiation, follicular development and oocyte competence. Results from animal models provide compelling evidence of their physiological necessity, and human reported variants must be studied in depth regarding segregation, population frequency and functional consequence [3].

The clinical interpretation has to differentiate between diagnostics and therapeutic eligibility. Chromosomal analysis and FMR1 premutation testing are available to find non-iatrogenic cases of POI; sequencing may identify additional variants if carried out after appropriate counselling [4]. A proposed editing target requires a consistent phenotype, a plausible inheritance pattern and an association that functional variation changes gene function. Familial segregation and functional assays may reinforce this hypothesis, but importantly, outcomes vary from patient to patient due to incomplete penetrance and variable expression. Importantly, genetic counselling should provide

 Copyright © The Author(s)

the wider scope of this to relatives and reproductive decision-making without implying that a molecular diagnosis facilitates an editing treatment. This diagnostic value is clinically relevant, even when a direct address is not possible or not justifiable.

2.2. FMR1-associated ovarian dysfunction

The distinction between these allelic mechanisms underscores the importance of FMR1 in ovarian function. Generally, a premutation of 55–200 CGG repeats predisposes to fragile X-associated primary ovarian insufficiency (FXPOI) and aberrant ovarian aging. By contrast, the full mutation with >200 CGG repeats, due to methylation associated silencing, causes fragile X syndrome. It is important to recognise the premutation and full mutation not as two interchangeable causes of ovarian disease: they have vastly different transcriptional and epigenetic states, and POI is mainly seen in premutation carriers [3].

This difference is vital for interpreting editing experiments. Reactivating a silenced full-mutation allele in a neuronal model is addressing a different molecular problem to that of ovarian dysfunction linked to a transcriptionally and epigenetically active premutation. Consequently, it is not correct to assume that restoration of FMR1 expression in fragile X syndrome cells would fix ovarian pathology. May also be repeat length, tissue context, and the proposed disease mechanism all inform which of these three approaches to use (sequence editing, repeat excision, or epigenetic regulation) is biologically relevant.

2.3. Meiotic, oocyte and maternal-effect genes

Variants affecting meiotic chromosome pairing, recombination and segregation may lead to ovarian dysgenesis, causing depletion of oocytes or developmental arrest. The genes that have been found include STAG3, SYCE1, HFM1 and PSMC3IP. Furthermore, other regulators of the then-mentioned genes, like NOBOX and FIGLA, influence the reduction of ovarian reserves (follicle number) through changes in oocyte differentiation and follicular development in agreement with the literature so far [3]. While these genes converge on the goal, they also operate at different stages of development (indeed, the difference is manifested in that defects predating the time of the argument eliminating germ cells during fetal development may not necessarily respond with available therapeutic windows in comparison to defects affecting maturation of ameliorated oocytes that were available).Variants in TUBB8 affect spindle organization and meiotic progression, and WEE2 dysfunction can affect exit from metaphase II and pronuclear formation. Genes such as PADI6, TLE6 and NLRP5 are outside the phenotypic spectra of oocyte quality but they contribute to processes related to early embryonic development [3]. These examples illustrate why a normal ovarian reserve or a successful oocyte retrieval does not preclude a genetic cause. They also explain the value of using a phenotypically-led approach; for example, differentiation between dates of maturation arrest, fertilisation failure and rates of success during cleavage-stage arrest is not a matter of reassessing an infertility measure but treating different diagnostic categories.

2.4. Chromosomal abnormalities

Disorders of chromosomes may affect ovarian development through gene-dosage effects due to, changes in chromosome structure or affecting the stability of megatory Loblasiatino, with the study of X chromosome dosage effects on phenotypic features of XX individuals and with support of observations for this pathological condition predominantly complete or partial loss of an X chromosome that occurs in turner syndrome and coupled with early oocyte loss and gonadal dysgenesis. Karyotype heterogeneity and mosaicism, however, seem to be associated with permutations in ovarian function. Women who have a 46,XX cell line and motor axle maturation separate from the presence of a 46,XX* karyotype have a higher chance of spontaneous conception over those with more severe gonadal impairment [3, 8]. Consequently, clinical counselling should not express absolute certainty that every woman with Turner syndrome is infertile.

The X chromosome, as well as other chromosomal imbalances (the X chromosomal imbalance) May pose a threat to reproductive function or pregnancy viability. They are an effect of a secondary single base pair (SNP) mutation. The repair of a missing chromosome or the pathogenicity of aneuploidy is not taken for granted simply because of the traditional

Copyright © The Author(s)

Cas9- sequence editing. This hypothesis of a chromosome approach is still very much speculative, partners should keep in mind clinical assessment and fertility preservation, where appropriate and specialized reproductive counseling. The underlying strategies in Turner syndrome in order to get pregnant needs to be advanced, not only to get rid of congenital tests. [8].

2.5. Complex, neuroendocrine and acquired conditions

Polycystic ovary syndrome (PCOS), is a disease of varied composition as defined by isolated characteristics of hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology, also called the three crown conditions of PCOS, metabolic aspects differing between people. It is caused by interacting genetic and environmental factors, not one pathogenic mutation 9. Susceptibility variants – which may influence endocrine or metabolic pathways, but not a single "defective" allele with traits (if altered could cure the condition) according to research supported by just a few genes. Therefore, it is more likely that CRISPR is predictive of mechanisms and related causal pathways rather than a blanket-genomic therapy strategy as a PCOS cure. Fertility management is as for the clinical phenotype, i.e. evidence-based recommendations. Genetic structure of endometriosis is as intricate as any other condition that we know about, including in endometriosis. Researchers performed a major genome-wide association meta-analysis that identified 42 significant loci consisting of 49 distinct signals of association related to mechanisms and tissue regulation common to pain and inflammation. These are not obviously an easy hole in a bone that can be plugged. In the end, the infertility that accompanies endometriosis is not a mystery: deformation of anatomy cannot be excluded and the constant duty-cycles of the pelvic or endometrial environments have been implicated. Editing a susceptibility locus would give rise to an inevitable psychological treatment result and genetic risk reduction does not equal restoration of fertility. Kallmann syndrome is something else entirely: genetically diverse congenital hypogonadotropic hypogonadism with very special defects in sense of smell. Disruption of the developmental pathways involving gonadotropin-releasing hormone neurons can be caused by Variants of ANOS1 formerly known as KAL1, and FGFR1. Reproductive function can be induced with hormonal therapy which can restore fertility, revealing that genetic diseases can be treated without genome correction [11]. This is in stark contrast to Asherman's syndrome, which is an acquired intrauterine scarring, frequently after instrumentation of a pregnant uterus. Though it is one of the considerations when evaluating female infertility, it is not an inherited genetic syndrome. It is mainly treated with hysteroscopic adhesiolysis, although obstetric and reproductive restrictions might continue to exist [12].

3. CRISPR Mechanisms and Editing Platforms

3.1. Cas9 targeting and DNA repair

In the commonly used Streptococcus pyogenes Cas9 system, the guide RNA recruits nuclease to the complementary genomic sequence next to a protospacer-adjacent motif (PAM). A double-strand break occurs at a specified sequence in the pretaneous cleavage of strands opposite the polynucleotide: the HNH and RuvC nuclease domains [5, 6]. While sequence recognition is programmable, recognition and the ensuing event may have inherent errors. Availability of a specific PAM sequence, base pairing between the guide and target, and the cellular environment all influence the effectiveness and result of editing.

Cellular repair of this break mostly occurs through non-homologous end joining, which results in insertions/deletions, used for creating gene-disruption models. Homology directed repair can introduce a specific sequence when a suitable donor sequence is available, but its efficiency can be influenced by the cell type/host and the alternate DNA repair pathways present in the cell [6]. Each of these modes of DNA repair is suited to specific purposes in a laboratory: A knockout may clarify the working of a gene but is not valid as a correction of a loss-of-function disease. The difference between nuclease targeting and the variable outcomes of DNA repair is shown in Fig. 1.

 Copyright © The Author(s)




Figure 1. Conceptual schematic of conventional CRISPR–Cas9 genome editing. Guide-dependent recognition and a compatible PAM precede double-strand cleavage.

Non-homologous end joining can generate variable insertions or deletions, whereas homology-directed repair may incorporate a specified sequence using a repair template. The diagram is an original schematic based on established mechanisms [6]; it does not imply that precise correction occurs in every edited cell. PAM, protospacer-adjacent motif.

Efficient cleavage in reproductive tissues is an inadequate performance measure on its own. An editing strategy must also preserve genomic fidelity, developmental competence and aimed reproductive phenotype. Mature oocytes, proliferating somatic cells and cleavage-stage embryos vary in biology; thus, an editing approach that works well in one compartment does not necessarily extend to another. Consequently, the distinction of editing efficiency and functional benefit must be taken into account throughout experimental design and interpretation.

Guide selection and experimental validation should be matched to the intended objective. Disruptive editing may be reasonable for establishing gene importance; meanwhile, therapies continued refinement to keep the normal allele, retaining the notion of providing appropriate function. With help of an appropriate mix of alternative guides, unedited controls and independent edited models it's possible to tell if a gene-dependent phenotype is reproducible effect, or is a side-effect of a guide [6]. An optimal cell population selection may be a survival or selection of rather than a correction over all cells in the original population with evidence of double-strand break: the evaluation of cellular stress and structural genomic harm occuring. These considerations play a critical role when there is limited testable reproductive tissue that leads to only lower replication or to an adverse reliance on a few cluster favourable observations.

3.2. Base and prime editing

Base editors bring software-based DNA-targeting to nucleotide-modifying enzymes. It consisted initially of a cytosine base-editing (CBE) system, which allows the unprogrammed double stranded break (DSB) or donor template required for base editing, via the C-to-T conversion, or the reverse G-to-A change [13]. A-to-G conversion is now available with the addition of adenine base editors to the methodology. Even though these systems can be quite appealing for particular pathogenic substitutions, the sequence context and an editing window limits activity. Unwanted bystander changes to nearby nucleotides, off-target activity present, and occasionally altered repairs exist, but not often enough to be removed from consideration [13, 14].

Copyright © The Author(s)

Prime editing combines a Cas9 nickase and a reverse transcriptase via a prime-commanding guide RNA that defines targeting and desired sequence changes. The initial report cited the generation of a wide array of substitutions, insertions and deletions in human cells, all done without a double-strand break or supplemental donor DNA [15]. It is plausible that this wider mention is relevant for the troubled infertility-related variants due to heterogeneous nature of the condition. However, correction efficiency and by-products differ between targets and cell types. Avoiding a programmed double-strand break does not establish safety in oocytes or embryos, and neither base editing nor prime editing has discovered a routine clinical solution for female infertility [7, 14].

3.3. Gene regulation and epigenome editing

The DNA binding properties of sequence-directed DNA binding without nuclease cleavage can be retained in the use of catalytically inactive Cas9, dCas9. It can recruit transcriptional regulators or epigenetic effectors to drive gene expression or alter chromatin state [6]. This uses a different mechanism than permanent sequence correction, and it might also be informative when dysregulation is the cause of disease rather than a coding variant. This step should be studied carefully for efficiency, specificity, and correct expression levels. An intervention that raises expression in an in vitro system may not accurately model regulatory differences in fertility, such as normal physiological changes during follicular development or at the time of implantation. Epigenome editing may therefore be considered separate modality, not an automatic substitute for genome correction.

4. Experimental Applications in Reproductive Biology

4.1. Disease modelling and functional validation

CRISPR-based perturbation provides an efficient way to examine whether a candidate gene is required for a reproductive process. Barrelier cells or animal models to perturb the integrity of can provide insights into the pathways regulating follicular development, meiosis and embryogenesis. Causal knowledge can be reinforced by isogenic models—which generate an otherwise matched genetic background with a defined variant for either unifying or correcting purposes [6] and is particularly valuable when variants of uncertain significance are identified by sequencing. Experimental phenotypes, however, have to be placed into the context of the model's species, developmental stage and tissue.

Not every important reproductive genetics study used CRISPR (it was specifically that TUBB8 variants are important for human oocyte meiotic arrest by observing end points related to microtubule behaviour, spindle assembly and maturation in family sequencing and functional studies that include mutant complementary RNA microinjection into oocytes; they do establish a gene–phenotype causal relationship but this study does not represent CRISPR correction or fertility rescue. Divide up discovery, perturbation, and rescue experiments to avoid the therapeutic evidence imprecision.

An approach with complementary design is usually more useful for functional studies than one editing readout. You introduce a particular disease variant causing a specific disease, or you correct disease-causing variant to test if you can restore phenotype. This highlights the need for independent controls as culture conditions and genetic background may influence reproductive cells. While mechanisms for secondary gene activation might be an alternate possibility, the effect of overexpression of the endogenous loci is distinct and may not reflect normal levels of physiological dose [3, 6]. What would be the important observations for an ovarian target depends on the emerging defect: e.g. follicular maturation, hormonal signalling and oocyte competence. These are intermediate endpoints: they should drive further investigations without reaching pregnancy or live-birth outcomes.

4.2. Human preimplantation embryo research

Fogarty and colleagues employed CRISPR–Cas9 to knock POU5F1, the gene for master transcription factor OCT4, in donated human preimplantation embryos [17]. The study involved developmental timing, lineage-associated gene expression, and transcriptional consequences of the induced breakage of the genome. From these results, the authors concluded, genome editing can be a valuable technology for investigating human embryogenesis and that the findings derived

 Copyright © The Author(s)

from one model cannot be directly applied to another. Anyways, this was an experiment looking at what genes do, not which infertility mutation to correct.

It is key to note that no embryo transfers or pregnancy endpoint was a part of the study. The assessment of blastocysts gives you some idea of developmental competence early enough for first tests (that are associated with later implantation, livebirth or the health of women after delivery to live birth and/or further reproductive outcomes). Thus, embryo research can be enlightening in identifying the means by which early developmental failure occurs without positing clinical reproductive editing is feasible. Their interpretation must also consider the role of DNA damage in causing a particular phenotype, as well as the associated disruption of the targeted gene if chromosomal integrity hasn't been thoroughly evaluated. [17, 18].

4.3. FMR1 epigenetic rescue and its limits

Liu et al. implemented dCas9-mediated DNA methylation editing to reverse the patient derived fragile X syndrome in induced pluripotent stem cells and neurons [19] with this approach, a demethylating effector was used to target the expanded repeat region and effects on gene expression, chromatin changes and neurons function were examined. FMR1 reactivation and amelioration of neuronal phenotype proved to be relevant molecular and cellular rescue, however it is essentially a study on a neurodevelopmental disease model. No oocytes, follicles, ovarian reserve, or reproductive success was examined. Additionally, the epigenetically silenced full mutation is mechanistically distinct from premutation that is mostly associated with POI [3, 19]. While these results demonstrate that targeted epigenetic regulation is achievable, they are not evidence that CRISPR can restore female fertility. Ovarian therapy would be reliant on direct evidence in an appropriate premutation model, well-justified mechanism of target action and endpoints that demonstrate ovarian and reproductive functionality, not neuronal rescue.

4.4. Endometrial pathways and assisted reproduction

Endometrial receptivity is regulated by very well-orchestrated hormonal, cellular and molecular processes. Leukaemia inhibitory factor, or LIF, and HOXA10 are components of the relevant pathways but LIF persistence is not a result of uterine condition alone; the pathway making clear although uterine editing improves implantation without this being obvious. Li et al found that LIF outcomes in stimulating miR-27a-3p and HOXA10 in bovine endometrial epithelial cells in culture through STAT3 pathway [20]. Their study looked at signaling and expression-related responses, not genome correction, embryo transfer, or pregnancy So they should be cited as mechanistic endometrial study, not successful CRISPR treatment.

On its way into assisted reproduction, genome editing is expected to contribute primarily in indirect ways: confirming genetic diagnoses, revealing failure mechanisms that occur at particular stages and creating experimental platforms for discovery of therapeutics [7]. These efforts increase biological understanding without performing editing on patients or potential progeny. IVF claims that are related to a decreased utilization of IVF does not require clinical significance, e.g. cumulative live birth when appropriate, but only molecular markers. There is no ground for putting CRISPR correction into the daily workflows of in vitro fertilisation with the contemporary evidence.

5. Technical and Biological Safety Constraints

5.1. Off-target activity and unintended on-target changes

Off-target editing takes place when an editing complex acts on unintended sites. Whether this happens and in what proportion depends on the guide design, nuclease properties, exposure and genomic context [6, 14]. However, even if an accidental change hits a functional sequence, the clinical impact of a site of edit cannot be inferred just from the presence of an edit. In combination, sensitive detection and biological interpretation are required. Likewise, it does not ensure genome editing safety if other sites are found to be free of changes in a limited sample of predicted sites. Unintended On-Target Damage Another Issue. Large deletions and complex structural rearrangements in a circuit of mouse and cultured human-cell models of Cas9-induced breaks were identified by Kosicki Z. et al [21]. It was not a study of human embryos but it does highlight that local sequence assays don't

Copyright © The Author(s)

always reflect the full extent of cutting related damage. A structurally anomalous segment of a chromosome could still bear a correctly directed hairpin that has already been cleaved. Safety assessment must consider not only where edits happen, but the mechanism of repair at the target region, not that having high on target processivity is reason enough to consider it safe.

5.2. Embryonic DNA repair and mosaicism

It also provides more evidence of conducive repair studies to direct studies on embryos. Out of 53 breaks analysed, 27 were reported since through non-homologous end Joining, five through homology-directed repair and 21 were inherited unresolved (non-repaired), they reported continuing unresolved double strand breaks in research embryos. Though, these results are the third year report of Kubikova and colleagues, including its methodological and evidence limitations.

This result cannot be extrapolated to an actual proportion of all embryos, outcomes are dependent on specific target, guide, time, developmental stage, and method of assay. That said, the studies show hazards requiring actions to be taken rather than treated as nothing. Mosaicism creates more uncertainty in the event of an embryo with a combination of unedited cells and cell with different intended or accidental modifications. A biopsy samples only part of the embryo and may not contain all lineages. Thus will apparently corrected cells in sample are correct throughout or if there are other abnormalities in other cells [18, 22, 24] that is not justifiable. Therefore, the operation design is the pivot to build the safety argument. Short reads for local sequencing results can provide sufficient sequencing information via targeted sequencing, although it is preferable to supplement this with an exhaustive copy-number profiling approach; but large defects are mostly discerned accruing on extensive long-range tests or genomic analysis [18, 21, 22]. No process is perfect when working with a small number of embryos, as we need to employ techniques that require you to amplify few embryonic cells or cannot further test the (the same) sample. If an affirmation of no inadvertent changes, one must also give coverage and detection limits of the assay by anyone making a claim to a precision. Results should be split on the proportion of edited embryos, the cells analysed and the alleles sequenced: these are not interchangeable terms that can be quite often used interchangeably. While its testing is also important, comprehensive testing is insufficient for assuring developmental safety and may never circumvent any issues regarding mosaicism sampling.

5.3. Delivery, tissue specificity and long-term effects

Cell therapy is particularly challenging when treating reproductive tissues composed of distinct populations of cells that are involved with distinct functions. Editing granulosa cells is not the same as editing oocytes, and the fact that a target of a therapy methodis the somatic cells, but an ovarian intervention may still expose germ cells. In order for a delivery system to be therapeutically preferable, it must have efficient access to the relevant compartment and avoid systemic exposure and non-intended germ line modification. Different viral and non-viral systems limitations, but none is inherently safe, or has found an application in the ovary [6, 14].

In all cases, adeno-associated virus vectors have a payload capacity limitation, however the larger base and prime editors could even be split vector approaches or alternative delivery strategies. While non-viral delivery and transient ribonucleoprotein exposure can mitigate some concerns related to extended editor expression, incorporation, distribution, and consistency remain dependent on context [14]. In addition to immediate effects on cell viability, long-term assessment must also encompass evaluation of endocrine function, reproductive performance, pregnancy outcomes, and, if appropriate, development of descendants. Potentially heritable applications require substantially more evidence, as effects may extend beyond the individual to be treated [24].

6. Discussion

6.1. Matching the intervention to the disease mechanism

Gene editing has a strong basis in the genetics literature, but not so much reason to use in a therapeutic setting. Monogenic disorders with well-defined pathogenic variants are clearer targets than defects in PCOS or endometriosis, but even clearly defined deleterious rectification could preclude a later developmental

 Copyright © The Author(s)

consequence [3, 9, 10]. The correct cell population needs to be edited, and at an appropriate nature. Ovary somatic-cell therapy is fundamentally different than transgenerational embryo editing to prevent a disease allele (which would not rescue the patient's own ovarian reserve).

A significant shortcoming could be seen when one compares the studies described here. The TUBB8 study showed a variant-associated oocyte dysfunction, the OCT4 study examined human embryogenesis, the FMR1 study recapitulated an epigenetic rescue, and the bovine endometrial study described signaling [16, 17, 19, 20]. Although they are scientifically relevant, they evaluate alternate issues and are not a continuous set of evidence showing improved infertility. Future articles should delineate the comparison group, the intervention, the primary endpoint, and keep gene expression, oocyte maturation, implantation or live birth as distinct outcomes. The clinical literature provided a key comparison for the refinement of editing strategies. Current POI, Turner syndrome and PCOS guidance emphasizes diagnosis, individualized counseling and established reproductive management [4, 8, 9]. A future molecular intervention should demonstrate incremental benefit over appropriate care, not simply a technically successful edit. The evidence considered here has been derived in many species, tissues, with many interventions and across many different endpoints which precludes direct comparison of efficacy across platforms. Cell-based and embryo studies are also varied in the length of follow-up and the extent of genomic assessment. Accordingly, the review offers justification for the mechanistic conclusions and recognition of research gaps rather than a summary of the improvement of fertility or a technology rating based on clinical success.

6.2. Somatic and heritable editing

This is an example of somatic editing that targets non-germline cells, and is not meant to be heritable. Besides, the modulation of extra-ovarian gametes, their ancestral progenitors, or embryos poses a heritable risk if the affected embryo develops into a pregnancy [24, 25]. This difference is much more relevant, in the ovarian setting, this is due to the fact that immediate anatomical proximity does not race biological cogent combarianism of the somatic / germline compartments. It signifies that there is a requirement for evidence to support that the portrayed result in each well was actually distributed in the same way and that it behaved within the limits of potential concern.

While the risk of heritable editing raises concerns that exceed only the domains of conventional informed consent regarding treatment. Non-consensual exposure affects potential offspring and future generations while life-long effects, which are uncertain, cloud proper estimation of proportional benefit. Prospective benefits are also weighed against the availability of reproductive alternatives, taking into account feasibility, limitations, and individual acceptance [24]. Whether to prevent the transmission or the preference to have genetically related offspring, by themselves, do not constitute evidence that embryo editing is needed or justified. Any new intervention demanded a disease-specifically informed and not a generic one, based on the advancement of technology.

6.3. Governance and public trust

The 2018 announcement of children born after using CCR5-edited embryos for pregnancy was characterized as an unapproved heritable editing intervention to confer protection against against HIV but not for female infertility [24]. This represents a failure of scientific, oversight, responsible extrapolation. It does not establish whether or not it is possible to use it for reproductive editing, and one cannot see it as a global ban on heritable editing. The Regulations and research acceptable to practice vary by region. In order to create well-informed and accountable authorities these critical enabling structures (registries, transparency, opportunities for a public and transparent discussion, mechanisms for dealing with unsafe or unlicensed activities) should be regulated by the WHO [25]. Governing matter that includes setting an affordable price for services/services, not being unfairly driven by commercial advantage, and the potential for reproductive tourism to evade safeguards. Communication is the most critical factor: there is no medical certainty of pregnancy in experiment correction of a molecular error. It is replication and tools which can be rightfully answerable for how these tools were modified instead of moral that better editors have nonetheless settled the

Copyright © The Author(s)

ethical debate sure attendance in credible translation.

6.4. A proportionate translational pathway

Short-term work will also include investigation in disease-relevant models for rigorous verification of variants and for predicted interventions that are not the generation of pregnancies from embryos edited post fertilization. Edit can be used to reverse disease-type phenotypes in patient-based cell systems and systematic design of isogenic comparisons. Reproductive studies need to identify the relevant biological time window and implementation of another method to assess genomic integrity [6, 14, 24]. Check the variant and the base and prime editing chemistry that comes from it. However, due to their reduced reliance on double strand breaks, they should prove themselves, not oversell themselves.

A solid evidence pathway includes molecular confirmation with functional rescue, relevant reproductive outcomes, and long-term safety evaluation. Favorable clones cannot substitute for the performance of the whole organism, and so reported denominators, failed edits, and miscreation of small changes must be disclosed. The architecture of this International Commission. Before conducting heritable clinical trials, it is important to ensure that they are conducted with high precision, negligible changes, developmental assessment, and lifelong follow-up [24]. These limitations are far more burdensome than simply observing a corrected sequence. Until those gaps are filled, CRISPR's role in the treatment of infertility is best viewed as a research and discovery platform rather than a proven treatment [7]. Reproductive assessment should be performed on candidate interventions already evaluated in animals and it is more than just a successful mating or a positive laboratory result. Of interest were most of the people who conceived, had viable offspring and showed pertinent abnormalities in the mother or her offspring. They were well suited to serve as disease comparators. Those metrics were used exclusively in the above series of studies. Clinical assessment should be based on treatment burden, failed cycles and those managed at home after the end of treatment course. Specific treatment and full disclosure of results preclude the selection of a few cases in which the technique was technically successful for selective recitation. Investigations with longer-term implications of early gametogenesis or early embryogenesis is advised [24]. However, they do not override these parameters in principle—they simply express the biological evidence needed to verify the underlying hypothesis: a relevant and justifiable therapeutic effect of FIT ROSENO-Y.

7. CONCLUSION

CRISPR-Cas9 has enabled the study of genetic drivers of female infertility to an unprecedented degree. Many defined monogenic disorders can serve as test cases while chromosomal abnormalities and complex conditions are biology cannot be resolved by simple sequence correction warranting caution. The conventional nuclease, base editing, prime editing, and epigenome regulation technologies each have unique benefits, but must all be validated in the appropriate reproductive context. Implementation of genetic concepts with potential clinical relevance including functional genetics and some selected molecular or cellular rescue experiments have been demonstrated here but not restored female fertility. Looped modifications to the genome, mosaic tissues and secreted factors and unproven long-term consequences leave many technical challenges to overcome for translation into intervention. Heritable applications may also require appropriate governance proportionate to risk by down the associated line to be discussed intergenerationally. A now precise role for CRISPR therefore remains disease modelling, target validation, and mechanistic discovery for safe therapeutic interventions in the future of testing such claims, demonstrating reproducible reproductive efficacy, ongoing safety monitors and ethical clinical pathways should details beyond molecular correction alone.

DECLARATIONS

Ethics approval and consent to participate: Not applicable to this narrative review, which reports no newly collected human or animal data.

Conflicts of interest

The authors report no conflicts of interest.

Copyright © The Author(s)

Funding

No funding was received for this study.

Data availability

No new datasets were generated or analysed for this manuscript.

Author contributions

Both authors contributed to conceptualization, methodology, investigation, data analysis, and manuscript preparation. Both authors reviewed and approved the manuscript.

REFERENCES

1. World Health Organization. Infertility [Internet]. Geneva: World Health Organization; 2025 Nov 28 [cited 2026 Nov 6]. Available from: https://www.who.int/news-room/fact-sheets/detail/infertility

2. World Health Organization. 1 in 6 people globally affected by infertility: WHO [Internet]. Geneva: World Health Organization; 2023 Apr 4 [cited 2026 Nov 6]. Available from: https://www.who.int/news/item/04-04-2023-1-in-6-people-globally-affected-by-infertility

3. Yatsenko SA, Rajkovic A. Genetics of human female infertility. Biol Reprod. 2019;101(3):549-566. doi:10.1093/biolre/ioz084.

4. ESHRE, ASRM, CREWHIRL and IMS Guideline Group on POI; Panay N, Anderson RA, Bennie A, Cedars M, Davies M, Ee C, et al. Evidence-based guideline: premature ovarian insufficiency. Climacteric. 2024;27(6):510-520. doi:10.1080/13697137.2024.2423213.

5. Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096. doi:10.1126/science.1258096.

6. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157(6):1262-1278. doi:10.1016/j.cell.2014.05.010.

7. Sahin GN, Seli E. Gene editing using CRISPR-Cas9 technology: potential implications in assisted reproduction. Curr Opin Obstet Gynecol. 2025;37(3):141-148. doi:10.1097/GCO.0000000000001022.

8. Gravholt CH, Andersen NH, Christin-Maitre S, Davis SM, Duijnhouwer A, Gawlik A, et al. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2023 Aarhus International Turner Syndrome Meeting. Eur J Endocrinol. 2024;190(6):G53-G151. doi:10.1093/ejendo/lvae050.

9. Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-2469. doi:10.1210/clinem/dgad463.

10. Rahmioglu N, Mortlock S, Ghiasi M, Moller PL, Stefansdottir L, Galarneau G, et al. The genetic basis of endometriosis and comorbidity with other pain and inflammatory conditions. Nat Genet. 2023;55(3):423-436. doi:10.1038/s41588-023-01323-z.

11. Yadav RK, Qi B, Wen J, Gang X, Banerjee S. Kallmann syndrome: diagnostics and management. Clin Chim Acta. 2025;565:119994. doi:10.1016/j.cca.2024.119994.

12. Khan Z. Etiology, risk factors, and management of Asherman syndrome. Obstet Gynecol. 2023;142(3):543-554. doi:10.1097/AOG.0000000000005309.

13. Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016;533(7603):420-424. doi:10.1038/nature17946.

14. Zeballos C MA, Gaj T. Next-generation CRISPR technologies and their applications in gene and cell therapy. Trends Biotechnol. 2021;39(7):692-705. doi:10.1016/j.tibtech.2020.10.010.

15. Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, et al. Search-and-replace genome editing without double-

Copyright © The Author(s)

strand breaks or donor DNA. Nature. 2019;576(7785):149-157. doi:10.1038/s41586-019-1711-4.

16. Feng R, Sang Q, Kuang Y, Sun X, Yan Z, Zhang S, et al. Mutations in TUBB8 and human oocyte meiotic arrest. N Engl J Med. 2016;374(3):223-232. doi:10.1056/NEJMoa1510791.

17. Fogarty NME, McCarthy A, Snijders KE, Powell BE, Kubikova N, Blakeley P, et al. Genome editing reveals a role for OCT4 in human embryogenesis. Nature. 2017;550(7674):67-73. doi:10.1038/nature24033.

18. Alanis-Lobato G, Zohren J, McCarthy A, Fogarty NME, Kubikova N, Hardman E, et al. Frequent loss of heterozygosity in CRISPR-Cas9-edited early human embryos. Proc Natl Acad Sci U S A. 2021;118(22):e2004832117. doi:10.1073/pnas.2004832117.

19. Liu XS, Wu H, Krzisch M, Wu X, Graef J, Muffat J, et al. Rescue of fragile X syndrome neurons by DNA methylation editing of the FMR1 gene. Cell. 2018;172(5):979-992.e6. doi:10.1016/j.cell.2018.01.012.

20. Li Q, Chen Y, Adeniran SO, Qiu Z, Zhao Q, Zheng P. LIF regulates the expression of miR-27a-3p and HOXA10 in bovine endometrial epithelial cells via STAT3 pathway. Theriogenology. 2023;210:101-109. doi:10.1016/j.theriogenology.2023.07.013.

21. Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol. 2018;36(8):765-771. doi:10.1038/nbt.4192.

22. Zuccaro MV, Xu J, Mitchell C, Marin D, Zimmerman R, Rana B, et al. Allele-specific chromosome removal after Cas9 cleavage in human embryos. Cell. 2020;183(6):1650-1664.e15. doi:10.1016/j.cell.2020.10.025.

23. Kubikova N, Esbert M, Titus S, Coudereau C, Savash M, Fagan J, et al. O-075 Deficiency of DNA double-strand break repair in human preimplantation embryos revealed by CRISPR-Cas9 [abstract]. Hum Reprod. 2023;38 Suppl 1:dead093.089. doi:10.1093/humrep/dead093.089.

24. International Commission on the Clinical Use of Human Germline Genome Editing. Heritable human genome editing. Washington (DC): National Academies Press; 2020. doi:10.17226/25665.

25. World Health Organization. Human genome editing: recommendations [Internet]. Geneva: World Health Organization; 2021 [cited 2026 Nov 6]. Available from: https://www.who.int/publications/i/item/9789240030381

 Copyright © The Author(s)